In their research brief published November 02, 2023, Deutsche Bank analysts downgraded the Moderna Inc stock from Hold to Sell with a price target of $60. The latest trade, Performances and Moving ...
Nearly 1.8 million chickens in Colorado will be sent to slaughter due to the latest outbreak of bird flu. Meanwhile, ...
The U.S. Department of Health and Human Services announced a partnership with Moderna to develop a vaccine for Avian ...
CureVac's share price has plummeted over 90% in the past five years due to vaccine efficacy issues and legal disputes. Learn ...
As fears of a pandemic mount, the biotech company’s mRNA vaccine trial is set to release Phase 1/2 results later this year, ...
CureVac NV, a German biopharma company with its U.S. headquarters in Boston, is restructuring after signing a licensing deal ...
GSK reached a licensing agreement with mRNA-vaccine developer CureVac worth up to $1.8 billion to develop its vaccines for ...
Results from Moderna’s early studies of the bird flu shot are expected in the next few weeks. The U.S. government contract is ...
CIDRAP: HHS Awards Moderna $176 Million To Develop MRNA H5 Avian Flu Vaccine The US Department of Health and Human Services ... Flu Vaccine Rights In Up To $1.56 Billion Deal GSK struck a deal to buy ...
The first large trial of a COVID and flu vaccine combo suggests it boosts immune protection even more than single-target ...